The stock of Vaxcyte Inc (PCVX) has gone down by -7.15% for the week, with a -16.33% drop in the past month and a 23.19% rise in the past quarter. The volatility ratio for the week is 5.02%, and the volatility levels for the past 30 days are 4.28% for PCVX. The simple moving average for the last 20 days is -10.61% for PCVX stock, with a simple moving average of 16.81% for the last 200 days.
Is It Worth Investing in Vaxcyte Inc (NASDAQ: PCVX) Right Now?
The stock has a 36-month beta value of 0.97. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PCVX is 120.00M, and at present, short sellers hold a 7.44% of that float. On November 14, 2024, the average trading volume of PCVX was 982.62K shares.
PCVX) stock’s latest price update
Vaxcyte Inc (NASDAQ: PCVX) has seen a decline in its stock price by -2.77 in relation to its previous close of 99.38. However, the company has experienced a -7.15% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-12 that — VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 — — VAX-31 Adult Indication: Breakthrough Therapy Designation Granted by FDA; Company Plans to Initiate Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 —
Analysts’ Opinion of PCVX
Many brokerage firms have already submitted their reports for PCVX stocks, with Mizuho repeating the rating for PCVX by listing it as a “Buy.” The predicted price for PCVX in the upcoming period, according to Mizuho is $69 based on the research report published on December 07, 2023 of the previous year 2023.
Needham gave a rating of “Buy” to PCVX, setting the target price at $58 in the report published on January 03rd of the previous year.
PCVX Trading at -13.37% from the 50-Day Moving Average
After a stumble in the market that brought PCVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.18% of loss for the given period.
Volatility was left at 4.28%, however, over the last 30 days, the volatility rate increased by 5.02%, as shares sank -18.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.47% lower at present.
During the last 5 trading sessions, PCVX fell by -7.15%, which changed the moving average for the period of 200-days by +43.47% in comparison to the 20-day moving average, which settled at $108.09. In addition, Vaxcyte Inc saw 53.87% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCVX starting from PICKERING GRANT, who sale 2,366 shares at the price of $103.89 back on Nov 07 ’24. After this action, PICKERING GRANT now owns 137,398 shares of Vaxcyte Inc, valued at $245,796 using the latest closing price.
PICKERING GRANT, the Officer of Vaxcyte Inc, proposed sale 2,366 shares at $104.08 during a trade that took place back on Nov 07 ’24, which means that PICKERING GRANT is holding shares at $246,253 based on the most recent closing price.
Stock Fundamentals for PCVX
Current profitability levels for the company are sitting at:
- -36.62 for the present operating margin
- 0.03 for the gross margin
The net margin for Vaxcyte Inc stands at -35.14. The total capital return value is set at -0.15. Equity return is now at value -21.06, with -20.08 for asset returns.
Based on Vaxcyte Inc (PCVX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -16.81. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -49.31.
Currently, EBITDA for the company is -464.88 million with net debt to EBITDA at 1.88. When we switch over and look at the enterprise to sales, we see a ratio of 762.94. The receivables turnover for the company is 0.81for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.88.
Conclusion
To sum up, Vaxcyte Inc (PCVX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
